Exact Sciences Corporation (NASDAQ:EXAS)‘s stock had its “outperform” rating reaffirmed by stock analysts at Leerink Swann in a research report issued to clients and investors on Monday. They currently have a $67.00 price target on the medical research company’s stock, up from their previous price target of $63.00. Leerink Swann’s price target suggests a potential upside of 14.86% from the stock’s current price.
Other equities research analysts have also recently issued reports about the company. Vetr raised Exact Sciences Corporation from a “sell” rating to a “hold” rating and set a $36.55 target price on the stock in a research note on Tuesday, July 25th. Lake Street Capital upped their price target on Exact Sciences Corporation from $30.00 to $41.00 and gave the company a “hold” rating in a report on Wednesday, July 26th. Roth Capital upped their price target on Exact Sciences Corporation from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, July 26th. Jefferies Group LLC upped their price target on Exact Sciences Corporation to $60.00 and gave the company a “buy” rating in a report on Tuesday, October 31st. Finally, Robert W. Baird upped their price target on Exact Sciences Corporation from $49.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 31st. Eight investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Exact Sciences Corporation currently has a consensus rating of “Buy” and a consensus price target of $49.98.
Shares of Exact Sciences Corporation (EXAS) opened at $58.33 on Monday. Exact Sciences Corporation has a 12 month low of $13.05 and a 12 month high of $63.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34.
Exact Sciences Corporation (NASDAQ:EXAS) last released its earnings results on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.07. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. The firm had revenue of $72.60 million for the quarter, compared to analysts’ expectations of $65.03 million. During the same period in the prior year, the firm posted ($0.36) earnings per share. The company’s quarterly revenue was up 158.4% on a year-over-year basis. equities analysts predict that Exact Sciences Corporation will post -1.14 EPS for the current year.
In other news, CEO Kevin T. Conroy sold 137,805 shares of the firm’s stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $59.14, for a total value of $8,149,787.70. Following the transaction, the chief executive officer now owns 967,867 shares of the company’s stock, valued at $57,239,654.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP D Scott Coward sold 29,115 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $1,373,063.40. Following the completion of the transaction, the senior vice president now directly owns 64,991 shares in the company, valued at approximately $3,064,975.56. The disclosure for this sale can be found here. In the last three months, insiders sold 415,178 shares of company stock worth $20,785,358. 4.00% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of EXAS. Prudential Financial Inc. raised its stake in shares of Exact Sciences Corporation by 3.0% in the first quarter. Prudential Financial Inc. now owns 11,141 shares of the medical research company’s stock worth $263,000 after buying an additional 320 shares during the period. Teachers Advisors LLC raised its stake in shares of Exact Sciences Corporation by 4.7% in the first quarter. Teachers Advisors LLC now owns 183,485 shares of the medical research company’s stock worth $4,334,000 after buying an additional 8,221 shares during the period. Renaissance Technologies LLC bought a new position in shares of Exact Sciences Corporation in the first quarter worth about $8,298,000. BlackRock Inc. grew its position in shares of Exact Sciences Corporation by 45,816.0% during the first quarter. BlackRock Inc. now owns 6,804,297 shares of the medical research company’s stock worth $160,718,000 after purchasing an additional 6,789,478 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its position in shares of Exact Sciences Corporation by 15.7% during the first quarter. Schwab Charles Investment Management Inc. now owns 483,849 shares of the medical research company’s stock worth $11,429,000 after purchasing an additional 65,619 shares in the last quarter. 85.65% of the stock is currently owned by hedge funds and other institutional investors.
Exact Sciences Corporation Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.